Causes of death in 1638 patients with polycythemia vera in the European collaboration on low-dose aspirin in polycythemia vera (ECLAP) study.
| All-cause mortality | 164 (10%) |
| Fatal thrombosis | 67 (4.1%) |
| Coronary heart disease | 25 (1.5%) |
| Congestive heart failure | 13 (0.8%) |
| Ischemic stroke | 13 (0.8%) |
| Pulmonary embolism | 6 (0.4%) |
| Other vascular death | 10 (0.6%) |
| Fatal bleeding | 7 (0.4%) |
| Cancer | 54 (3.3%) |
| Acute leukemia | 21 (1.2%) |
| Myelofibrosis | 1 (0.1%) |
| Other cancers | 32 (2.0%) |
| Other or unknown causes | 36 (2.2%) |
| All-cause mortality | 164 (10%) |
| Fatal thrombosis | 67 (4.1%) |
| Coronary heart disease | 25 (1.5%) |
| Congestive heart failure | 13 (0.8%) |
| Ischemic stroke | 13 (0.8%) |
| Pulmonary embolism | 6 (0.4%) |
| Other vascular death | 10 (0.6%) |
| Fatal bleeding | 7 (0.4%) |
| Cancer | 54 (3.3%) |
| Acute leukemia | 21 (1.2%) |
| Myelofibrosis | 1 (0.1%) |
| Other cancers | 32 (2.0%) |
| Other or unknown causes | 36 (2.2%) |